Lymphoma

Overview

Lymphoma develops when lymphocytes or related immune cells acquire genetic changes that allow uncontrolled growth and survival. It can arise in lymph nodes, spleen, bone marrow or extranodal organs such as the stomach, skin, brain or lungs. Because the lymphatic system extends throughout the body, lymphoma can present almost anywhere. ^{[1] [2]}

Most non-Hodgkin lymphomas arise from B cells, but T-cell and NK-cell lymphomas also occur. Some types are indolent and grow slowly for years, while others are aggressive and require urgent therapy. Hodgkin lymphoma has its own biology and staging approach. The exact cell lineage and molecular profile are essential because two lymphomas with similar symptoms can require very different treatments. ^{[1] [2]}

Enlarged lymph nodes are common and are usually caused by infection rather than cancer. Concern rises when nodes persist, enlarge progressively, are firm or fixed, occur with systemic symptoms or are accompanied by abnormal blood tests or imaging. A lymphoma diagnosis cannot be made from node size alone and should not be inferred from nonspecific symptoms such as fatigue. ^{[1] [2] [3]}

Symptoms and warning signs

Possible symptoms include painless lymph-node enlargement in the neck, armpit or groin, fatigue, itching, unexplained fever, drenching night sweats and unintentional weight loss. Chest lymph nodes can cause cough or pressure symptoms, while abdominal disease can cause pain or fullness. Extranodal lymphoma may produce organ-specific symptoms rather than obvious lymphadenopathy. ^{[1] [2]}

Rapidly enlarging masses, breathing difficulty, facial or neck swelling, new neurologic symptoms, severe abdominal pain or signs of tumor lysis can require urgent assessment. People already diagnosed with lymphoma should seek prompt care for fever during immunosuppressive treatment because neutropenic infection can become life threatening quickly. ^{[1] [2]}

Diagnosis

Diagnosis requires tissue. Excisional lymph-node biopsy is often preferred when feasible because architecture helps classify lymphoma, although image-guided core biopsy is used in many settings. Pathology combines morphology, immunohistochemistry, flow cytometry, cytogenetics and molecular tests to define the subtype. Fine-needle aspiration alone is often insufficient for full classification. ^{[1] [2]}

After diagnosis, staging can include PET/CT or CT, blood counts, metabolic tests, LDH and selected bone-marrow evaluation depending on subtype. Viral tests such as hepatitis B, hepatitis C or HIV may be important before immunosuppressive therapy. Cardiac function, fertility issues and other baseline tests are assessed when treatment could affect those systems. ^{[1] [2] [3]}

Persistent lymphadenopathy can result from viral or bacterial infection, autoimmune disease, sarcoidosis, metastatic cancer and medication reactions. Leukemia can overlap biologically with some lymphomas. The differential is narrowed by node distribution, duration, blood findings and pathology rather than by one symptom or scan. ^{[2] [3]}

Causes, risk factors and clinical context

Risk factors vary by subtype and include age, immune suppression, certain autoimmune disorders, previous chemotherapy or radiation and selected infections such as Epstein–Barr virus, HIV, HTLV-1 or Helicobacter pylori. Most people with lymphoma have no single preventable cause, and routine population screening is not recommended for asymptomatic adults. ^{[1] [2]}

Indolent lymphomas can remain stable for years and may be observed without immediate treatment, whereas aggressive lymphomas can double rapidly and require prompt therapy. Some aggressive lymphomas are highly curable. Relapse patterns and surveillance differ by subtype, which is why the precise pathology label should always accompany the general word “lymphoma.” ^{[1] [2] [3]}

Complications and why the diagnosis matters

Complications can come from the cancer or its treatment. Bulky disease can compress airways, blood vessels or organs. Bone-marrow involvement can cause anemia, infection risk or bleeding. Treatment can cause neutropenia, infertility, neuropathy, cardiac effects or secondary malignancies depending on the regimen. Tumor lysis syndrome is an acute metabolic risk in rapidly responsive high-burden disease. ^{[1] [2]}

Prognosis varies enormously. Early-stage Hodgkin lymphoma and several aggressive non-Hodgkin lymphomas have high cure rates with modern therapy, while indolent lymphomas may be managed as chronic relapsing diseases. Prognostic tools use subtype, stage, age, laboratory findings and treatment response; population statistics cannot predict an individual outcome. ^{[1] [2] [3]}

Treatment and management

Treatment is selected by subtype, stage, symptoms and patient factors. Options include multi-agent chemotherapy, monoclonal antibodies, small-molecule targeted therapy, immune checkpoint treatment, radiation, CAR-T cell therapy and stem-cell transplantation. Some indolent asymptomatic lymphomas are monitored with active surveillance until treatment is clinically needed. ^{[1] [2]}

Supportive oncology care includes infection prevention, vaccination planning, antiemetics, growth-factor support when indicated, management of anemia and thrombosis risk, fertility counseling and psychosocial support. Tumor lysis prevention may include hydration and uric-acid-lowering treatment in high-risk patients. Nutrition and exercise are individualized during therapy. ^{[1] [2] [3]}

There is no single “lymphoma chemotherapy.” Regimens are highly subtype specific, and incorrect treatment can reduce efficacy or add toxicity. New fever during neutropenia is an emergency. Supplements and herbal products should be discussed with the oncology team because of drug interactions and bleeding or liver risks. ^{[1] [2]}

Follow-up, recovery and prevention

Follow-up after treatment focuses on symptoms, physical examination and selected laboratory or imaging tests. Excessive routine imaging is avoided in some lymphoma types because of radiation exposure and limited benefit. Survivorship care addresses cardiovascular risk, fertility, endocrine effects, second cancers and vaccination depending on prior therapy. ^{[1] [2]}

Most lymphoma cannot be prevented through a single behavior. HIV prevention and treatment, avoidance of unnecessary immune suppression, treatment of certain chronic infections when indicated and general cancer-risk reduction may lower risk in selected settings. There is no screening blood test that reliably detects lymphoma in healthy people. ^{[1] [2] [3]}

Special situations and care pathway

Children, older adults, pregnant patients and people with HIV or organ transplants require specialized protocols. Some lymphomas are strongly associated with immune deficiency and may improve when immune suppression can be reduced. Central nervous system lymphoma and primary cutaneous lymphomas follow different diagnostic and treatment pathways from common nodal disease. ^{[1] [2] [3]}

A standard pathway is to evaluate persistent suspicious lymphadenopathy, obtain an adequate tissue biopsy, establish exact histologic and molecular subtype, stage the disease, assess treatment fitness and then choose a subtype-specific regimen. Response is measured with standardized criteria, often including PET/CT for FDG-avid lymphomas. ^{[1] [2]}

When to seek urgent medical care

Urgent evaluation is needed for breathing difficulty, facial swelling from possible superior vena cava obstruction, rapidly progressive neurologic symptoms, severe infection during treatment or fever in a patient known to be neutropenic. These problems can evolve quickly and should not wait for a routine oncology visit. ^{[1] [2]}

Sources

1. National Cancer Institute — Lymphoma — Patient Version
2. National Cancer Institute — Adult Non-Hodgkin Lymphoma Treatment
3. National Cancer Institute — Adult Hodgkin Lymphoma Treatment

This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.